Introduction
============

Postmenopausal osteoporosis (PO), primary type of osteoporosis, is regarded as a systemic skeletal disease characterized by compromised bone strength predisposing to an increased risk of fracture ([@b1-etm-0-0-7326]). Clinically, major manifestations of PO patients are low bone mass density (BMD), a fracture or even vertebral compression fracture occurring during routine daily activities without a specific fall or injury ([@b2-etm-0-0-7326]). In consequence, PO imposes a great burden on life of both individuals and their families. Currently, usual treatments for postmenopausal women with osteoporosis mainly include vitamin D, estrogens, bisphosphonates, and calcitonin ([@b3-etm-0-0-7326],[@b4-etm-0-0-7326]). Thus, an effective approach to overcome these limitations is an urgent need and a huge challenge for PO related research.

Simultaneously, previous studies have demonstrated that low BMD is the optimal predictor of fracture risk in asymptomatic PO ([@b5-etm-0-0-7326],[@b6-etm-0-0-7326]). Hence, a comprehensive understanding and explanation for molecular mechanism underlying the progression of BMD reduction is critical for PO patients. Increasing proofs showed that long non-coding RNAs (lncRNAs) are able to competitively adjust messenger RNAs (mRNAs) expression levels via sharing common microRNA (miRNA) binding sites with mRNAs ([@b7-etm-0-0-7326],[@b8-etm-0-0-7326]). In addition, identifying lncRNA competitively regulated pathways (LCRPs) give potential for uncovering molecular mechanism and exploring functions of lncRNAs in complicated human disease ([@b8-etm-0-0-7326]).

Pathway structure information helps to understand the physiology of diseases and the functions of the biological system ([@b9-etm-0-0-7326]). Moreover, Li *et al* suggested that key local sub-regions, rather than complete pathways, could subtly explain the etiology of diseases ([@b10-etm-0-0-7326],[@b11-etm-0-0-7326]). This finding revealed that more attention should be focused on sub-pathways rather than entire pathways ([@b12-etm-0-0-7326]). Therefore, in this study, we aimed to identify abnormal sub-pathways competitively regulated by lncRNAs through integrating lncRNA-mRNA expression profiles and pathway topologies for PO patients. The results might provide powerful evidence and give insights for uncovering the potential molecular mechanism underlying PO.

Materials and methods
=====================

Using lncRNA-mRNA expression data, the inference of abnormal sub-pathways between PO patients and normal samples consisted of four steps. The first step was to construct interesting lncRNA-mRNA pairs by Pearsons correlation coefficient (PCC) algorithm. Secondly, LCRPs were gained for PO patients. Thirdly, sub-pathways were detected dependent on the shortest distance similarity and the LCRP network topology. Ultimately, abnormal sub-pathways were determined by the Wallenius approximation methods via evaluating the statistical significance of sub-pathways.

### Recruitment of lncRNA-mRNA expression data

The interactions between lncRNAs and mRNAs were built by media of miRNAs. Thus the first part was to download the known lncRNA-miRNA and miRNA-mRNA interactions from the experimentally validated small non-coding RNAs target Base (starBase) and miRecords, respectively. Here, the straBase (<http://starbase.sysu.edu.cn/>) offers a comprehensive exploration for lncRNA-miRNA interactions curated from published studies ([@b13-etm-0-0-7326]). While the miRecords (<http://mirecords.umn.edu/miRecords>) are considered as an integrated resource not only for experimental miRNA-target interactions but also for target prediction programs ([@b14-etm-0-0-7326]). Furthermore, the lncRNA-mRNA competitively regulated relationships were defined by meeting to the two conditions concurrently: i) hypergeometric test ([@b15-etm-0-0-7326]) of shared miRNAs satisfying the criterion P\<0.05; and ii) Jaccard coefficient ([@b16-etm-0-0-7326]) of shared miRNAs ranking in top 20%. Consequently, 7,693 interactions (covering 835 lncRNAs and 1,749 mRNAs) were retained, termed with background lncRNA-mRNA interactions for PO patients.

Gene expression profiles with accessing number GSE56815 for PO patients were acquired from Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo>). The data were deposited on Affymetrix Human Genome U133A Array \[HG-U133A\], and comprised of 40 PO samples and 40 control samples. In order to optimize the data regardless of the terms of quality and quantity, standard pretreatments and normalizations ([@b17-etm-0-0-7326],[@b18-etm-0-0-7326]) were conducted on GSE56815. Next, the preprocessed probes were converted into gene structures immediately. As a result, 12,437 genes were obtained from the dataset for PO patients. With an attempt to increase the correlations between background lncRNA-mRNA interactions and PO patients, 12,437 genes were mapped to these interactions, and only the intersected lncRNAs and mRNAs were reserved as lncRNA and mRNA data for PO in the subsequent analyses.

### Construction of interesting lncRNA-mRNA pairs

Using the lncRNA and mRNA data, the co-expression probability for any pair of lncRNA-mRNA was assessed by the PCC algorithm. The PCC is a measure of the linear correlation between two variables, and its values (*r*) range from +1 to −1, where +1 is total positive linear correlation, 0 is no linear correlation, and −1 is total negative linear correlation ([@b19-etm-0-0-7326]). Subsequently, the Fisher\'s *Z*-transformation was applied to evaluate the statistical significance for *r*, which converts *r* to the normally distributed variable *Z* ([@b20-etm-0-0-7326],[@b21-etm-0-0-7326]). The Fisher\'s *Z*-transformation of *r* was computed by the following formula:
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When Z goes from negative infinity to positive infinity, P distributes from 0 to 1, and any value of P will uniquely be matched with a value of Z and vice versa ([@b21-etm-0-0-7326]). If a pair of lncRNA-mRNA had a P\<0.05, it would be regarded as interesting lncRNA-mRNA pair of PO patients for further exploitation.

### Identification of LCRPs

The KEGG pathway enrichment analysis was carried out on gene lists in pretreated GSE54400 (DAVID, <http://david.ncifcrf.gov>). Particularly, Fisher\'s exact test was employed to determine the statistical significance of pathways ([@b22-etm-0-0-7326]). The P-values were corrected by the false discovery rate (FDR) in Benjamini & Hochberg method ([@b23-etm-0-0-7326]). Pathways with P\<0.001 were considered to be significant between PO patients and control samples. These significant pathways were converted into undirected graphs and kept the original pathway structural information using R packages ([@b10-etm-0-0-7326]). Then, lncRNAs in the interesting lncRNA-mRNA pairs were embedded into pathway graphs as nodes through linking to their regulated-mRNAs. As a consequence, LCRP network for PO was gained, including lncRNA-mRNA competitively regulated edges and lncRNA nodes. In addition, these lncRNA nodes were named as signature nodes in LCRP network.

### Location of sub-pathways

During this step, sub-pathways for PO were located according to the shortest distance similarity combined with LCRP network topology. We chose any two of signature nodes randomly and computed the shortest path between them. If the amount of molecules between each signature pair was less than *n* then they were integrated into one node. Simultaneously, if the node number in the molecule sets within pathway was more than *k*, they would be thought as sub-pathways competing and regulated via signature lncRNAs. Specifically, the factor *n* controlled the intensity of regulated pathways, whereas *k* parameter measured the size of this sub-pathway. In this study, we applied *k* = 8 and *n* = 1 as default parameters.

### Investigation of abnormal sub-pathways

For purpose of evaluating whether the sub-pathways were competing and regulated by signature lncRNAs comparing random Wallenius approximation methods were implemented to test the statistical significance. Here, the Wallenius approximation methods is a generalization of the hypergeometric distribution where items are sampled with bias ([@b24-etm-0-0-7326]). Particularly, it was executed by BiasedUrn model in R package ([@b25-etm-0-0-7326]). In detail, a weight (*W*) was computed for every sub-pathway, which indicated the intensity of competing regulation via signature lncRNAs associated with the sub-pathway.
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P~G~ was the number of mRNAs in this sub-pathway, and G~L~ stood for the number of mRNAs competitively regulated by signature lncRNAs within this sub-pathway. Subsequently, supposing that *x* was the number of interesting mRNAs in interesting lncRNA-mRNA pairs; *N* referred to the amount of mRNAs in the gene expression data; *m~1~* was on behalf of the number of mRNAs associated with this sub-pathway; and *m~2~* represented the number of interesting mRNAs annotated into this sub-pathway, a corrected P-value was produced for the candidate sub-pathway as the following formula:
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Moreover, the cut-off for abnormal sub-pathways between PO and controls was P\<0.01.

Results
=======

### Interesting lncRNA-mRNA pairs

In this study, 7,693 background lncRNA-mRNA interactions involved in 835 lncRNAs and 1,749 mRNAs were recruited based on the starBase and miRecords when setting the thresholdings as P\<0.05 and top 20% Jaccard distribution. To make these interactions more correlated to PO, we mapped 12,437 genes in pre-processed GSE56815 to them, and only took the intersections. As a result, a total of 44 lncRNAs and 1,498 mRNAs which had intersections with all genes were gained to construct random lncRNA-mRNA pairs. An *r* value was assigned to each lncRNA-mRNA pair using the PCC method, and then a P-value was calculated according to the Fisher\'s *Z*-transformation test. The cut-off for interesting lncRNA-mRNA pairs between PO patients and control samples was P\<0.05 in the present study. As displayed in [Table I](#tI-etm-0-0-7326){ref-type="table"}, in total 75 interesting lncRNA-mRNA pairs (representing 17 lncRNAs and 74 mRNAs) were identified. The most interesting pair between DLEU2 and SEC24A possessed the most significant P of 5.44E-06, and the next two pairs were CROCCP2-CUL5 (P=2.08E-04) and JRK-FGFR2 (P=2.37E-04).

### LRCPs

As described above, the KEGG pathway enrichment analysis was carried out on 12,437 genes in the gene expression dataset. A total of 42 significant pathways with P\<0.001 were identified for PO patients ([Table II](#tII-etm-0-0-7326){ref-type="table"}). We found that PI3K-Akt signaling pathway (P=2.18E-09), cell cycle (P=2.07E-08), and p53 signaling pathway (P=2.91E-07) were the three most significant pathways. In addition, each significant pathway was assigned to an ID, and the pathway stood by the end of four of the ID in the subsequent analysis. Next, 42 KEGG pathways were converted into undirected graphs that retained their original pathway structural information, and then the 17 lncRNAs were embedded into the graphs as signature nodes by linking to their regulated-mRNAs. Consequently, the total 42 significant pathways could be connected to lncRNAs by the regulation of mRNAs, and thus 42 LCRPs were explored for PO. In detail, 16 lncRNA-mRNA interactions were enriched in the cell cycle. Besides, 11 lncRNAs regulated PI3K-Akt signaling pathway through 15 mRNAs since one lncRNA could regulate multiple mRNAs synchronously.

### Abnormal sub-pathways

After identification of LCRPs for PO, their sub-pathways were explored through the integration of the shortest path similarity and LCRP network topology. The ID for sub-pathways were in accordance with the corresponding LCRPs, for example, the first sub-pathway for PI3K-Akt signaling pathway (ID: 4151) was described as 4151_1 and the second one was 4151-2. In fact, these sub-pathways mostly belonged to 14 of 42 LCRPs. Immediately, the Wallenius approximation methods was used to evaluate the statistical significance of sub-pathways and executed dependent on R package BiasedUrn. Consequently, a total of 14 abnormal sub-pathways were determined under the condition of P\<0.01, as shown in [Table III](#tIII-etm-0-0-7326){ref-type="table"}.

In order to illustrate the correlations more directly and clearly, a sub-pathway network for signature nodes and abnormal sub-pathways was constructed and visualized by Cytoscope ([Fig. 1](#f1-etm-0-0-7326){ref-type="fig"}). As one LCRP might have several sub-pathways, we selected the ID for corresponding LCRPs to represent its multiple sub-pathways in the sub-pathway network conveniently. The network comprised of 66 nodes and 129 edges, of which 14 were LCRPs, 14 signature lncRNAs and 38 mRNAs. Then, we calculated the topology centrality of this network using the degree index. Interestingly, the degree for YLPM1 and PI3K-Akt signaling pathway (ID: 4151) in both was 58, and followed Neurotrophin signaling pathway (ID: 4722, degree = 48) and TTTY15 (degree = 47). These nodes with high degree might play a more important role in the progression of PO patients, which also were suitable for sub-pathways.

Taking the top three ranked abnormal sub-pathways as examples, we extracted their sub-networks for the sub-pathway network, as shown in [Fig. 2](#f2-etm-0-0-7326){ref-type="fig"}. The first one, abnormal sub-pathway for PI3K-Akt signaling pathway (ID: 4151_2), consisted of 21 nodes (7 signature lncRNAs, 10 interesting mRNAs and 4 genes) and 23 edges, such as TTTY15, DLEU2 and UBXN8. There were 8 interesting mRNAs, 4 signature lncRNAs, 4 genes and 23 edges in the sub-network for long-term potentiation (ID: 4720_1). The signature lncRNA DLEU2 connected more modes than the others, and thus, it was critical for this sub-pathway. As for the sub-network for pathways in cancer (ID: 5200_2), a total of 27 nodes and 37 edges were mapped on it, of which 17 interesting mRNAs, 8 signature lncRNAs and 2 genes, especially for UBXN8.

Discussion
==========

Although numerous studies have concentrated on the relevance of lncRNAs to tumorigenesis as well as other diseases, the exact functions and activities of lncRNAs in PO progression remains unclear. Accurate molecular mechanisms underlying PO are controversial. For instance, Stuss *et al* considered that hormonal changes, which occurred throughout perimenopause and the immediate postmenopausal years, led to the accelerated BMD loss by stimulating the receptor activator of nuclear factor-κβ (RANK) and its ligand (RANKL) production ([@b26-etm-0-0-7326]). To shed new light on the dispute of PO, in this study, we revealed the pathological mechanism of PO from the view point of lncRNAs.

Since the RNA competitive interaction can influence the various critical functions of disease, investigating LCRPs not only can gain insight into the potential mechanism but also help investigate the lncRNAs functional role in disease ([@b12-etm-0-0-7326]). Thus, we identified abnormal lncRNAs between PO and controls by the integration of lncRNA-mRNA expression profiles and pathway network topology. As lncRNAs and mRNAs were not worked on directly, we built their relations through the shared miRNAs from lncRNA-miRNA and miRNA-mRNA interactions, and obtained interesting lncRNA-mRNA pairs for PO. To enhance the feasibility and confidence of our study, we chose the significant KEGG pathways as graphs to link lncRNA to pathways, and consequently obtained LCRPs. It was revealed that signature lncRNAs combined with topology of LCRPs could efficiently give light on positioning of lncRNA-regulated sub-regions ([@b12-etm-0-0-7326]). Under this condition, abnormal sub-pathways between PO patients and controls were detected by the Wallenius approximation methods. A total of 14 abnormal sub-pathways were investigated, such as sub-pathways of PI3K-Akt signaling pathway and long-term potentiation. Besides, we uncovered several critical lncRNAs that regulated the important abnormal sub-pathways, for example, TTTY15, DLEU2 and UBXN8. The mRNAs in the sub-network of sub-pathway might be biomarkers for treatment and prevention of PO to some extent. On the basis of these results, the potential molecular mechanism of PO should be clarified.

Taking PI3K-Akt signaling pathway for an example, it is activated via multiple types of toxic insults or cellular stimuli and adjusts the fundamental functions of cells (i.e. proliferation, transcription, growth, translation, and survival) ([@b27-etm-0-0-7326]). Generally, the PI3K and AKT combined with mTOR pathways are deregulated in human cancer leading to genetic alterations in their components or upstream activation of cell-surface receptors ([@b28-etm-0-0-7326]). In this study, we also found that mTOR signaling pathway was a significant pathway for PO patients, which confirmed a previous study. In addition, Sabine *et al* revealed that deregulation of PI3K/AKT pathway genes contributed to the endocrine resistance of breast cancer ([@b29-etm-0-0-7326]), which indicated that this signaling pathway correlated with the endocrine changes in women. Thus, we might infer that the abnormal regulations of certain parts in PI3K-Akt signaling pathway caused the BMD loss in PO patients by affecting their endocrine changes.

In conclusion, we have successfully identified abnormal sub-pathways for PO patients compared with normal controls by integrating lncRNA related analysis and pathway topologies. The findings might shed new light on revealing potential molecular mechanism underlying PO, and provide several signature lncRNAs with significant functions in the progression of PO. Further studies should focus on validation of these signature lncRNAs.
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###### 

Interesting lncRNA-mRNA pairs with P\<0.05.

  Pairs                  Pairs                                
  ----------- ---------- ------------ ----------- ----------- --------
  DLEU2       SEC24A     0.00000544   CROCCP2     PTEN        0.0183
  CROCCP2     CUL5       0.000208     TTTY15      CACNG4      0.0188
  JRK         FGFR2      0.000237     TTTY15      HMGA2       0.0191
  CROCCP2     KAT2B      0.000317     YLPM1       EIF4G3      0.0203
  DLEU2       ACSL4      0.000458     PVT1        CCND1       0.0209
  DLEU2       DNAJC3     0.000522     DLEU2       PPP1CC      0.0210
  DLEU2       STX7       0.000679     LINC00312   SMAD4       0.0217
  LINC00342   SOCS1      0.0013       DLEU2       LSM1        0.0224
  YLPM1       ITPR1      0.0015       JRK         IGF1R       0.0224
  JRK         RARA       0.0016       DLEU2       UTP6        0.0226
  LINC00312   RBL2       0.0016       SEMA3B      CHEK1       0.0231
  DLEU2       AP3S1      0.0017       DLEU2       PRPF40A     0.0239
  UBXN8       CDKN1B     0.0018       YLPM1       EIF5B       0.0251
  DLEU2       SPCS3      0.0020       LINC00342   MYCN        0.0253
  DLEU2       KPNA1      0.0022       MCF2L-AS1   TERT        0.0261
  LINC00312   RB1        0.0023       DLEU2       EIF2B1      0.0265
  DLEU2       PRKAA1     0.0027       TTTY15      GYS2        0.0272
  DLEU2       PAIP1      0.0031       DLEU2       PLA2G4A     0.0274
  TTTY15      GEMIN7     0.0032       SLC38A3     PIK3R2      0.0278
  MAP3K14     CCND2      0.0032       C11orf95    E2F1        0.0293
  DLEU2       PPP3R1     0.0041       YLPM1       NOTCH2      0.0317
  DLEU2       PPP1R12A   0.0051       DLEU2       GABARAPL2   0.0325
  TTTY15      AMT        0.0083       SEMA3B      FGF2        0.0331
  DLEU2       SEC11A     0.0084       LINC00342   BMPR2       0.0342
  DLEU2       PPP2R5C    0.0087       YLPM1       MDN1        0.0343
  UBXN8       KRAS       0.0095       SEC22B      ESR1        0.0350
  DLEU2       CUL2       0.0097       JRK         RPS6KA1     0.0373
  YLPM1       ARHGDIA    0.0115       YLPM1       ZYX         0.0379
  UBXN8       NRAS       0.0121       JRK         EIF4EBP1    0.0392
  MCF2L-AS1   CDH1       0.0123       YLPM1       HSPA5       0.0432
  DLEU2       PPP3CA     0.0128       CROCCP2     NOTCH2      0.0435
  DLEU2       CSNK1G3    0.0136       DLEU2       ARHGEF6     0.0446
  JRK         GRIN2A     0.0156       DLEU2       BMS1        0.0447
  SEMA3B      IFNG       0.0157       LINC00663   ZNF764      0.0464
  UBXN8       PMAIP1     0.0165       TTTY15      CACFD1      0.0476
  CROCCP2     SIRT1      0.0168       TTTY15      CCNB2       0.0481
  LINC00663   ITPKA      0.0176       TTTY15      ATG4B       0.0499
  SPON1       SMO        0.0181                               

lncRNA, long non-coding RNA; mRNA, messenger RNA.

###### 

LCRPs with P\<0.001.

  Pathway ID   Pathway                                     P-value    Number of matched lncRNA-mRNA pairs
  ------------ ------------------------------------------- ---------- -------------------------------------
  hsa04151     PI3K-Akt signaling pathway                  2.18E-09   15
  hsa04110     Cell cycle                                  2.07E-08   16
  hsa04722     Neurotrophin signaling pathway              2.91E-07   13
  hsa04010     MAPK signaling pathway                      3.35E-07   11
  hsa04720     Long-term potentiation                      3.70E-07     9
  hsa04810     Regulation of actin cytoskeleton            7.25E-07     9
  hsa05218     Melanoma                                    2.00E-06   10
  hsa05219     Bladder cancer                              2.18E-06     5
  hsa05200     Pathways in cancer                          2.24E-06     9
  hsa05215     Prostate cancer                             4.69E-06   10
  hsa05212     Pancreatic cancer                           4.70E-06     7
  hsa05203     Viral carcinogenesis                        7.68E-06     6
  hsa05213     Endometrial cancer                          1.44E-05     6
  hsa05161     Hepatitis B                                 1.78E-05     7
  hsa04114     Oocyte meiosis                              1.98E-05     9
  hsa05223     Non-small cell lung cancer                  2.22E-05   10
  hsa05221     Acute myeloid leukemia                      2.46E-05     6
  hsa04370     VEGF signaling pathway                      3.64E-05     6
  hsa05214     Glioma                                      6.77E-05     9
  hsa04910     Insulin signaling pathway                   9.25E-05     9
  hsa05216     Thyroid cancer                              2.10E-04     4
  hsa05222     Small cell lung cancer                      2.51E-04     5
  hsa04150     mTOR signaling pathway                      3.72E-04     9
  hsa04730     Long-term depression                        3.72E-04     6
  hsa04066     HIF-1 signaling pathway                     6.64E-04     6
  hsa05031     Amphetamine addiction                       6.65E-04     5
  hsa04140     Regulation of autophagy                     6.74E-04     4
  hsa05166     HTLV--I infection                           6.99E-04     9
  hsa04662     B cell receptor signaling pathway           8.64E-04     5
  hsa04660     T cell receptor signaling pathway           1.28E-03     6
  hsa04510     Focal adhesion                              1.30E-03     6
  hsa03060     Protein export                              1.65E-03     3
  hsa05220     Chronic myeloid leukemia                    1.65E-03     7
  hsa04012     ErbB signaling pathway                      2.02E-03     3
  hsa04914     Progesterone-mediated oocyte maturation     2.13E-03     5
  hsa04650     Natural killer cell mediated cytotoxicity   2.89E-03     6
  hsa05210     Colorectal cancer                           3.82E-03     4
  hsa05211     Renal cell carcinoma                        4.78E-03     3
  hsa04664     Fc epsilon RI signaling pathway             5.90E-03     4
  hsa04724     Glutamatergic synapse                       6.96E-03     5
  hsa04115     p53 signaling pathway                       8.01E-03     5
  hsa03013     RNA transport                               8.48E-03     6

lncRNA, long non-coding RNA; mRNA, messenger RNA; LCRPs, lncRNA competitively regulated pathways.

###### 

Abnormal sub-pathways with P\<0.01.

  Sub-ID   Pathway                            Weight   P-value
  -------- ---------------------------------- -------- ----------
  4151_2   PI3K-Akt signaling pathway         1.4854   \<0.001
  4720_1   Long-term potentiation             1.6374   \<0.001
  5200_2   Pathways in cancer                 1.5475   \<0.001
  5215_1   Prostate cancer                    1.6374   \<0.001
  4810_1   Regulation of actin cytoskeleton   1.5146   1.11E-16
  4110_2   Cell cycle                         1.6521   2.22E-16
  4010_1   MAPK signaling pathway             1.2224   2.22E-15
  5223_1   Non-small cell lung cancer         1.4150   8.88E-15
  5218_2   Melanoma                           1.7370   6.59E-14
  5166_2   HTLV--I infection                  1.0000   1.26E-13
  4114_2   Oocyte meiosis                     1.4854   2.63E-12
  5214_1   Glioma                             1.4854   2.63E-12
  4150_1   mTOR signaling pathway             1.6781   7.00E-12
  4722_1   Neurotrophin signaling pathway     1.6781   7.09E-12
